Risk Factors for Retinal Hemorrhage after Photodynamic Therapy in Age-Related Macular Degeneration

Background: Subretinal or intraretinal hemorrhage may occur after photodynamic therapy (PDT). However, risk factors for post-PDT hemorrhage have not yet been investigated. Methods: We reviewed the medical records of patients who had undergone PDT for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Primary outcomes were the occurrences of hemorrhages at 2 and 12 weeks after PDT. To identify the risk factors of hemorrhages after treatment, ocular and systemic factors were investigated. The secondary outcome was visual acuity. Results: Ninety-two eyes from 92 patients were analyzed. New hemorrhages developed in 9 (9.8%) within 2 weeks and in 8 (8.3%) between 2 and 12 weeks after PDT. Hypertension [odds ratio (OR) 356.9, 95% confidence interval (CI) 3.7–34,487.1], minimally classic lesion (OR 53.4, 95% CI 2–1,429) and advanced age (OR 1.2, 95% CI 1–1.5) were related to hemorrhagic events within 2 weeks after PDT. A tendency toward recurrent hemorrhage was noted after repeat treatments (p < 0.05). Forty-four percent of the patients with a hemorrhagic event within 2 weeks after PDT experienced decreased vision. Conclusion: Hypertension, minimally classic lesion, advanced age and a previous hemorrhagic event were associated with the development of hemorrhage within 2 weeks after PDT.

[1]  H. Yatsuya,et al.  Seasonal variations of acute massive submacular haemorrhage associated with age-related macular degeneration , 2006, British Journal of Ophthalmology.

[2]  Jennifer I. Lim,et al.  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. , 2005, Archives of ophthalmology.

[3]  W. Inhoffen,et al.  Subfoveal hemorrhage after verteporfin photodynamic therapy in treatment of choroidal neovascularization , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  Jennifer I. Lim,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report , 2004, Retina.

[5]  N. Bressler Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. , 2003, American journal of ophthalmology.

[6]  J. Jonas VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Meta-Analysis of 2-Year Safety Results in Three Randomized Clinical Trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report , 2002, American journal of ophthalmology.

[7]  Simon P. Harding,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.

[8]  A. M. Verbeek,et al.  Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  R. Sperduto,et al.  Systemic hypertension and age-related maculopathy in the Framingham Study. , 1986, Archives of ophthalmology.

[10]  I. Georgalas,et al.  Retinal hemorrhage after photodynamic therapy in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[11]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[12]  N. Bressler,et al.  TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP. PHOTODYNAMIC THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION WITH VERTEPORFIN: TWO-YEAR RESULTS OF 2 RANDOMIZED CLINICAL TRIALS-TAP REPORT 2 , 2001 .

[13]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[14]  Oates Rp,et al.  Senile macular degeneration: a preliminary study. , 1982, Annals of ophthalmology.